Prevnar, the first pneumococcal vaccine that can be given to children under 2

April 2000

The FDA just approved Prevnar, the first pneumococcal vaccine that can be given to children under 2.

This is important. Children under 2 have the highest risk of invasive pneumococcal disease.

Prevnar is extremely effective for preventing pneumococcal bacteremia...meningitis...and pneumonia.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

alarming increase in type 2 diabetes in children and teens
Dermatology new prescription "nail polish" called Penlac
Supplements news that vitamin C might increase the risk of heart disease
Supplements huperzine A to improve memory and treat Alzheimer's
Diabetes how to switch Rezulin patients to one of the newer glitazones
Diabetes new devices will allow patients to test blood sugar from their arm, abdomen, or thigh
Diabetes pharmacists to get involved in diabetic foot screening
Women's Health doxylamine and pyridoxine combo is safe and effective for treating nausea and vomiting during pregnancy
SSRIs can cause patients to clench and grind their teeth
low doses of gabapentin (Neurontin) for muscle cramps
Cardiology which drugs to use to prevent stroke
Cardiology patients don't need to stop low-dose aspirin before ORAL surgery
Substance Use Disorder dextromethorphan abuse
Infectious Diseases Biaxin XL and regular Biaxin (clarithromycin) tablets
Infectious Diseases Prevnar, the first pneumococcal vaccine that can be given to children under 2
Hypertension now urging physicians to avoid treating hypertension with alpha blockers
Practice Propulsid (cisapride) will go off the market July 14, 2000